missing translation for 'onlineSavingsMsg'
Learn More
Learn More
STEMCELL Technologies Imatinib (Mesylate)
Description
- Imatinib mesylate is a first generation tyrosine kinase inhibitor that selectively targets certain tyrosine kinases, including ABL, platelet-derived growth factor receptor (PDGFR), and KIT (Druker, 2008; Müller)
- Inhibits proliferation of primary cultured human mesenchymal stem cells, and promotes adipogenic over osteogenic differentiation (Fierro et al.)
- Induces osteoblast differentiation in cultured osteoblastic cells, and reduces osteoclastogenesis in mouse bone marrow cultures (O'Sullivan et al.)
- In CML, Imatinib inhibits the oncoprotein BCR-ABL, the product of the Philadelphia chromosome gene fusion (Carroll et al.; Druker et al.), 1996)
- Inhibits autonomous erythropoiesis in peripheral blood mononuclear cells isolated from patients with polycythemia vera (Oehler et al.)
Specifications
Specifications
| CAS | 220127-57-1 |
| Synonym | CGP57148B; Gleevec; Glivec; STI-571 |
| Quantity | 25 mg |
| Molecular Formula | C29H31N7O · CH4SO3 |
| Purity | ≥98% |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?